Detail akcie Vaxart Rg online

Business Summary: Vaxart, Inc. is a clinical-stage biotechnology company that is primarily focused on the development of oral recombinant vaccines based on its Vector-Adjuvant-Antigen Standardized Technology (VAAST) proprietary oral vaccine platform. Its vaccines are designed to be administered using pills that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. Its development programs include pill vaccines designed to protect against norovirus (cause for acute gastroenteritis), coronavirus, including SARS-CoV-2 (COVID-19)), and influenza. In addition, it has generated preclinical data for its therapeutic vaccine candidate targeting cervical cancer and dysplasia caused by human papillomavirus. The Company's platform technology employs a vector-based approach and consists of various components, such as a vector (adenovirus type 5 (Ad5); an antigen (Ad5 DNA); an adjuvant (Toll-like receptor 3 (TLR3)), and its proprietary enteric-coated tablet.
Financial Summary: BRIEF: For the three months ended 31 March 2025, Vaxart Inc revenues increased from $2.2M to $20.9M. Net loss decreased 36% to $15.6M. Revenues reflect Government Contract increase from $1.6M to $19.3M, Royalty Income - Business increase from $585K to $1.6M. Lower net loss reflects pharmaceutical segment loss decrease of 38% to $14.9M. Basic Earnings per Share excluding Extraordinary Items increased from -$0.14 to -$0.07.